End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
770,000 KRW | -1.28% | -1.41% | +1.32% |
04-25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
04-25 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
Business Summary
Number of employees: 4,284
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Contract Development and Manufacturing Organization
72.4
%
| 2,337,523 | 77.9 % | 2,674,291 | 72.4 % | +14.41% |
Biopharmaceutical Development and Commercialization
27.6
%
| 663,772 | 22.1 % | 1,020,298 | 27.6 % | +53.71% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe
63.7
%
| 1,785,875 | 59.5 % | 2,353,845 | 63.7 % | +31.80% |
Americas
26.3
%
| 853,984 | 28.5 % | 971,055 | 26.3 % | +13.71% |
Other
6.9
%
| 206,690 | 6.9 % | 255,120 | 6.9 % | +23.43% |
South Korea
3.1
%
| 154,746 | 5.2 % | 114,569 | 3.1 % | -25.96% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 17-12-31 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Yong-Ho An
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
Hyung-Woo Moon
CMP | Compliance Officer | 54 | 16-12-31 |
Dong-Joong Kim
BRD | Director/Board Member | 59 | - |
James Choi
IRO | Public Communications Contact | 57 | 13-12-31 |
Sojeong Lee
LAW | General Counsel | - | 23-08-22 |
Connie Kim
PRN | Corporate Officer/Principal | - | 20-12-31 |
Park Yong
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
Jae-Wan Park
BRD | Director/Board Member | 69 | - |
Dong-Joong Kim
BRD | Director/Board Member | 59 | - |
Soon-Jo Kwon
BRD | Director/Board Member | 59 | - |
Geun-Nyeong Heo
BRD | Director/Board Member | 68 | 19-03-21 |
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 17-12-31 |
Eunice Kim
BRD | Director/Board Member | 65 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 71,174,000 | 17,974,713 ( 25.25 %) | 0 | 25.25 % |
Company contact information
SAMSUNG BIOLOGICS Co., Ltd.
300 Songdo Bio Way Yeonsu-gu
21987, Inchon
+
http://www.samsungbiologics.comSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.32% | 39.82B | |
-4.66% | 86.13B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- A207940 Stock
- Company Samsung Biologics Co.,Ltd.